Differential CD52 expression by distinct myeloid dendritic cell subsets: Implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation

Blood

Volumn 101, Issue 4, 2003, Pages 1422-1429

  Ratzinger, Gudrun ^b   Reagan, John L ^b   Heller, Glenn ^b   Busam, Klaus J ^b   Young, James W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIGEN; CD52 ANTIGEN; RITUXIMAB;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW CELL; CELL POPULATION; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG ACTIVITY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; LANGERHANS CELL; LYMPHOCYTE DEPLETION; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; NORMAL HUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; STEADY STATE; T LYMPHOCYTE;

EID: 0037441755     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1093     Document Type: Article

References (42)

1. Xia MQ, Tone M, Packman L, Hale G, Waldmann H. Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol. 1991;21:1677-1684.
2. Hart D, Fearnley D, Sorg U, Hock B. Non-lineage antigens and dendritic cells functional studies: the CMRF-56 monoclonal antibody identifies dendritic cells after brief culture of human peripheral blood mononuclear cells. In: Kishimoto T, Kikutani H, von dem Borne EGK, et al, eds. Leukocyte Typing VI. 6th ed. New York, NY: Garland Publishing; 1997:599-601.
3. Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood. 2002;99:2586-2591.
4. Rowan WC, Hale G, Tite JP, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol. 1995;7:69-77.
5. Xia MQ, Hale G, Waldmann H. Efficient complement-mediated lysis of cells containing the CAM-PATH-1 (CDw52) antigen. Mol Immunol. 1993;30:1089-1096.
6. Dyer M, Hale G, Hayhoe F, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 1989;73:1431-1439.
7. Isaacs JD, Wing MG, Greenwood JD, Hazelman BL, Hale G, Waldmann H. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin Exp Immunol. 1996;106:427-433.
8. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332:323-327.
9. Rebello P, Hale G. Pharmacokinetics of Campath-1H: assay development and validation. J Immunol Methods. 2002;260:285-302.
10. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol. 2000;12:574-581.
11. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071-1078.
12. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419-2425.
13. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
14. Bell D, Young JW, Banchereau J. Dendritic cells. Adv Immunol. 1999;72:255-322.
15. Hart DNJ. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 1997;90:3245-3287.
16. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor α. Blood. 1997;90:1458-1470.
17. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med. 1996;184:695-706.
18. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature. 1992;360:258-261.
19. + bone marrow precursors cultured with c-kit ligand, granulocytemacrophage colony-stimulating factor, and TNF-α. J Immunol. 1995;154:5851-5861.
20. Szabolcs P, Avigan D, Gezelter S, et al. Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-CFU intermediate. Blood. 1996;87:4520-4530.
21. + bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor α. J Exp Med. 1995;182:1111-1120.
22. + hemopoietic progenitors. J Immunol. 1996;157:1499-1507.
23. + progenitors. J Immunol. 2000;164:3600-3607.
24. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994;180:83-93.
25. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med. 1994;179:1109-1118.
26. Zhou L-J, Tedder TF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol. 1995;154:3821-3835.
27. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwai N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods. 1996;196:121-135.
28. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods. 1999;223:1-15.
29. 2 and tumor necrosis factor α cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med. 1997;186:1603-1608.
30. Jonuleit H, Kuhn U, Muller G, et al. Pro-Inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135-3142.
31. Jansen JH, Wientjens G-JHM, Fibbe WE, Willemze R, Kluin-Nelemans HC. Inhibition of human macrophage colony formation by interleukin 4. J Exp Med. 1989;170:577-582.
32. Weiner LM. Monoclonal antibody therapy of cancer. Semin Oncol. 1999;26:43-51.
33. Gilleece M, Dexter T. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood. 1993;82:807-812.
34. Gerritsen WR, Wagemaker G, Jonker M, et al. The repopulation capacity of bone marrow grafts following pretreatment with monoclonal antibodies against T lymphocytes in rhesus monkeys. Transplantation. 1988;45:301-307.
35. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood. 2000;95:2484-2490.
36. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86-89.
37. Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001;107:1581-1589.
38. Cooke K, Olkiewicz K, Clouthier S, Liu C, Ferrara J. Critical role for CD14 and the innate immune response in the induction of experimental acute graft-versus-host disease. Presented at: American Society of Hematology 43rd Annual Meeting and Exposition; Orlando, FL; 2001:776a.
39. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415.
40. Hill GR, Ferrara JLM. The primacy of the gastrointestinal tract as a target organ of acute graftversus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95:2754-2759.
41. Ordemann R, Hutchinson R, Friedman J, et al. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Clin Invest. 2002;109:1249-1256.
42. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med. 2002;8:575-581.